My personal understanding is the reason of this current situation is because RAC does not do any marketing or promotion on Zantrene at all.
There is not much news, or articles educating public on this drug, so only people here on HC spend hours and hours doing research and gathering information.
Understand RAC is trying to be under the radar, but if the company follows this strategy, then it is not easy to see “a higher SP”.
I think only when the management decided to open the door and start talking to the whole world about this drug, that could be the time we can see a higher SP. According to the timeline, this should be happening in Q4 CY2021.
Otherwise we can only be patient, wait and see the SP hanging around $3.30.
GLTA
Speculative M&A Transaction Analysis, page-650
-
- There are more pages in this discussion • 205 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add RAC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.65 |
Change
-0.040(2.37%) |
Mkt cap ! $281.2M | |||
| Open | High | Low | Value | Volume |
| $1.69 | $1.69 | $1.64 | $50.53K | 30.36K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 539 | $1.65 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.69 | 731 | 1 |
View Market Depth
| Last trade - 16.10pm 07/10/2024 (20 minute delay) ? |
| RAC (ASX) Chart |